Mainz Biomed (MYNZ) Competitors $1.63 -0.05 (-2.98%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$1.63 0.00 (0.00%) As of 09/5/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MYNZ vs. CLSD, DYAI, MAAQ, KZR, AKTX, RNTX, CASI, DARE, TRIB, and PMNShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include Clearside Biomedical (CLSD), Dyadic International (DYAI), Mana Capital Acquisition (MAAQ), Kezar Life Sciences (KZR), Akari Therapeutics (AKTX), Rein Therapeutics (RNTX), CASI Pharmaceuticals (CASI), Dare Bioscience (DARE), Trinity Biotech (TRIB), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. Its Competitors Clearside Biomedical Dyadic International Mana Capital Acquisition Kezar Life Sciences Akari Therapeutics Rein Therapeutics CASI Pharmaceuticals Dare Bioscience Trinity Biotech Promis Neurosciences Clearside Biomedical (NASDAQ:CLSD) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends. Does the media favor CLSD or MYNZ? In the previous week, Mainz Biomed had 2 more articles in the media than Clearside Biomedical. MarketBeat recorded 2 mentions for Mainz Biomed and 0 mentions for Clearside Biomedical. Clearside Biomedical's average media sentiment score of 0.00 beat Mainz Biomed's score of -0.50 indicating that Clearside Biomedical is being referred to more favorably in the media. Company Overall Sentiment Clearside Biomedical Neutral Mainz Biomed Negative Do analysts rate CLSD or MYNZ? Clearside Biomedical presently has a consensus target price of $4.20, suggesting a potential upside of 1,113.87%. Mainz Biomed has a consensus target price of $14.00, suggesting a potential upside of 758.90%. Given Clearside Biomedical's higher possible upside, equities research analysts plainly believe Clearside Biomedical is more favorable than Mainz Biomed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clearside Biomedical 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17Mainz Biomed 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has stronger earnings & valuation, CLSD or MYNZ? Mainz Biomed has lower revenue, but higher earnings than Clearside Biomedical. Clearside Biomedical is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClearside Biomedical$1.66M16.36-$34.35M-$0.37-0.94Mainz Biomed$890K8.39-$21.65M-$65.60-0.02 Is CLSD or MYNZ more profitable? Mainz Biomed has a net margin of 0.00% compared to Clearside Biomedical's net margin of -665.19%. Company Net Margins Return on Equity Return on Assets Clearside Biomedical-665.19% N/A -124.15% Mainz Biomed N/A N/A N/A Which has more volatility and risk, CLSD or MYNZ? Clearside Biomedical has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Do institutionals & insiders have more ownership in CLSD or MYNZ? 18.8% of Clearside Biomedical shares are owned by institutional investors. 6.7% of Clearside Biomedical shares are owned by insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryClearside Biomedical and Mainz Biomed tied by winning 7 of the 14 factors compared between the two stocks. Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.69M$3.13B$5.77B$9.91BDividend YieldN/A2.28%6.71%4.52%P/E Ratio-0.0220.9775.6126.09Price / Sales8.39290.13479.1187.80Price / CashN/A44.9736.9659.04Price / Book0.629.8711.456.09Net Income-$21.65M-$53.42M$3.28B$266.32M7 Day Performance-2.98%2.93%0.98%0.43%1 Month Performance10.88%9.85%7.86%4.55%1 Year Performance-87.52%15.74%62.81%26.11% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed2.0075 of 5 stars$1.63-3.0%$14.00+758.9%-87.8%$7.69M$890K-0.0230Short Interest ↑CLSDClearside Biomedical2.2396 of 5 stars$0.40-1.1%$4.20+942.7%-62.7%$31.97M$1.66M-1.0930DYAIDyadic International3.05 of 5 stars$0.87+2.4%$6.00+589.7%-28.3%$30.76M$3.49M-4.587Short Interest ↓Gap DownMAAQMana Capital AcquisitionN/A$3.68+1.1%N/A+1,181.9%$29.90MN/A0.001Gap UpKZRKezar Life Sciences2.6434 of 5 stars$4.00-1.5%$9.00+125.0%-29.8%$29.73M$7M-0.4160AKTXAkari Therapeutics3.0814 of 5 stars$0.89-4.0%$5.00+465.0%-76.5%$29.65MN/A0.009News CoverageShort Interest ↑Gap DownRNTXRein TherapeuticsN/A$1.18-7.1%N/AN/A$29.60MN/A0.009Gap UpCASICASI Pharmaceuticals3.7753 of 5 stars$2.43+3.0%$4.00+64.6%-64.3%$29.02M$28.54M-0.95180Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionDAREDare Bioscience2.1177 of 5 stars$2.08-1.9%$12.00+476.9%-37.7%$28.58M$10K-0.9730Analyst UpgradeTRIBTrinity Biotech0.8034 of 5 stars$1.55-1.3%N/A-86.8%$28.34M$61.56M-0.53480Short Interest ↑PMNPromis Neurosciences2.8478 of 5 stars$0.53-0.2%$4.33+710.6%-68.6%$27.76MN/A0.005Gap Down Related Companies and Tools Related Companies Clearside Biomedical Alternatives Dyadic International Alternatives Mana Capital Acquisition Alternatives Kezar Life Sciences Alternatives Akari Therapeutics Alternatives Rein Therapeutics Alternatives CASI Pharmaceuticals Alternatives Dare Bioscience Alternatives Trinity Biotech Alternatives Promis Neurosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYNZ) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersThe Altcoin That Could be Poised to Benefit Most from Trump’s ReturnWith Trump back in office, the crypto tide is turning fast. Regulation is easing. Momentum is building. And ac...Weiss Ratings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredWarren Buffett's Strangest AI InvestmentTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: Musk’s IRS move could blindside your retirementElon Musk just made a bold financial move — one that some say could hit retirements harder than any recession....American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
